Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. (Fed. Cir. 2023) | McDonnell Boehnen Hulbert & Berghoff LLP
In its recent review of a district court decision the Federal Circuit characterized as "a thorough opinion," the Federal Circuit affirmed invalidation for obviousness of four claims...
Pfizer Inc Teleflex Inc Supreme Court Teva Pharmaceuticals United States Inc Vanda Pharmaceuticals Inc District Court
Source: jdsupra.com